In recent years, several biologic antibodies have been clinically introduced such as omalizumab (anti-IgE), dupilumab (anti-IL-4), and mepolizumab (anti-IL-5), because IgE and Th2 cytokines (IL-4, IL-5, and IL-13) play crucial roles in allergic asthma pathogenesis [8,9,10,11]. This evidence concerns the gene IL5 and allergic asthma.